Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine Cycles in Esophageal Cancer CRT
NCT02603159Phase 3Unknown
- Sponsor
- First Affiliated Hospital of Henan University of Science and Technology
- Start
- Oct 2014
- Primary completion
- Dec 2017
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by First Affiliated Hospital of Henan University of Science and Technology. Status: unknown.
02
Drugs
capecitabine
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02603159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02603159.